Roche and Genentech were unable to sufficiently demonstrate the benefit of using Columvi in an earlier treatment setting for ...

The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...

Roche’s stock has lost 4.6% in the year so far compared with the industry’s decline of 1.6%.. Image Source: Zacks Investment Research Roche is evaluating Columvi in combination with other ...

(RTTNews) - Swiss drug major Roche Holding AG (RHHBY) announced Tuesday that the European Commission has granted conditional marketing authorisation for Columvi (glofitamab) to treat people with ...

Basel, 23 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today two-year follow-up data from the phase III STARGLO study. After a median follow-up of 24.7 months, data showed a 40% ...

Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response rate and a median duration of response of 1.5 years 1 Given over a fixed period of time, Columvi ...

Roche Holding said its Columvi drug helped lymphoma patients who had received at least one prior treatment live longer in a phase 3 clinical trial, meeting the primary goal of the study.